Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial ResultsGlobeNewsWire • 08/09/23
Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/04/23
Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GAGlobeNewsWire • 07/27/23
Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt DiseaseGlobeNewsWire • 07/24/23
Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and WarrantsGlobeNewsWire • 05/31/23
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and WarrantsGlobeNewsWire • 05/30/23
Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial ResultsGlobeNewsWire • 05/10/23
Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial ResultsGlobeNewsWire • 05/10/23
Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 DataGlobeNewsWire • 05/04/23
Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO MeetingGlobeNewsWire • 04/25/23
Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1GlobeNewsWire • 04/11/23
Belite Bio Reports Full-Year 2022 Operational Highlights and Financial ResultsGlobeNewsWire • 03/31/23
Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial ResultsGlobeNewsWire • 03/31/23
Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)GlobeNewsWire • 11/18/22